Does low-dose LBH589 increase the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells?
We hypothesized that combination of cisplatin and LBH589 can override cisplatin-associated resistance in ovarian cancer cells. These results provide initial evidence for testing this combination in clinical use.
Although these findings need to be confirmed in prospective studies, the role of school experience for children with SLDs seems highly relevant also for their psychological well-being.